US Bancorp’s BioAge Labs BIOA Stock Holding History

US Bancorp’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.1K	Buy	1,311 +1,095	+507%	+$19.8K	﹤0.01%	3000
2026 Q1	$3.78K	Buy	216 +94	+77%	+$1.81K	﹤0.01%	3649
2025 Q4	$1.61K	Buy	+122	New	+$1.08K	﹤0.01%	3791

Other funds holding BIOA

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

US Bancorp's BIOA Position: Q2 2026 in Review

US Bancorp increased its BioAge Labs (BIOA) stake by 507% in Q2 2026, buying an estimated $19.8K and bringing the position to 1,311 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3000.

US Bancorp first reported a position in BIOA in Q4 2025 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

US Bancorp held 1,311 shares of BioAge Labs worth $32.1K as of Q2 2026.
US Bancorp bought 1,095 BioAge Labs shares in Q2 2026, an estimated $19.8K.
BioAge Labs made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3000 holding.
US Bancorp first reported a position in BioAge Labs in Q4 2025 and has held it in 3 quarters since.
150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.